EUCTR2008-006763-36-DE进行中（未招募）不适用
Randomized, double-blind study comparing the immunogenicity of two different brands of human insulin for the treatment of diabetes
Marvel Life Sciences Limited0 个研究点目标入组 500 人开始时间: 2009年3月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[[1]male and female patients suffering from type 1 or type 2 diabetes mellitus for at least 6 months before randomization
- •[2]negative screening assay for antibodies against insulin before the start of treatment
- •[3]age 18-75 years
- •[4]Body Mass Index (BMI) =35 kg/m2
- •[5]informed consent given in a written form after being provided with detailed information about the nature, risks, and scope of the clinical trial as well as the expected desirable and adverse effects of the drug
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[1]known hypersensitivity against insulin or any of the inactive components of the formulations
- •[2]known extreme resistance to insulin (daily dose of more than 200 IU)
- •[3]severe renal failure (NKF stage 4-5) or patients on hemodialysis
- •[4]severe cardiac failure (NYHA III-IV)
- •[5]myocardial infarction within the last 6 months before randomization
- •[6]unstable angina pectoris
- •[7]stroke within the last 6 months before randomization
- •[8]liver failure with ascites
- •[9]severe peripheral vascular disease with ulceration or amputation
- •[10]cancer
- •[11]concomitant treatment with corticosteroids (except stable dose of inhaled corticosteroids)
- •[12]concomitant treatment with immunosuppressive agents (e.g. cyclosporine A, methotrexate, etc.)
- •[13]concomitant treatment with somatotropine
- •[14]pregnancy or lactation period in female patients
- •[15]severe physical or mental concomitant diseases that might hamper the realization of the trial according to protocol or the evaluation of efficacy or safety
- •[16]anamnestic or current alcohol abuse i.e. consumption of more than 10 units of alcohol per week or a history of alcoholism or drug/chemical abuse (one unit of alcohol equals 250 ml of beer, 125 ml wine or 25 ml of spirits)
- •[17]participation in another clinical trial within the last 12 weeks
- •[18]legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the study
- •[19]unreliability or lack of cooperation
- •[20]lack of a possibility to attend the visits required by protocol.
研究者
相似试验
已完成
3 期
A clinical trial Comparing the immunogenicity of two different brands of human Insulin for the treatment of diabetes.CTRI/2009/091/000862Spectrum Clinical Research Pvt Ltd500
进行中（未招募）
不适用
Randomized, double-blind study comparing the immunogenicity of two different brands of human insulin for the treatment of diabetesEUCTR2008-006763-36-BGMarvel Life Sciences Limited500
进行中（未招募）
不适用
Randomized, double-blind, study to compare the incidence and intensity lf neurologic and pschiatic adverse events of efavirenz when given as a stepped dosage (200 mg qd for 6 days, 400 mg qd for 7 days and 600 mg qd from the day 14 farward) with the usual dosage (600 mg qd from first day)Pacientes infectados por el VIH a los que su medico responsable les haya prescrito efavirez como parte de su tratamiento antiretroviralMedDRA version: 6.0Classification code 10008919EUCTR2005-003243-31-ESuis Fernando López Cortés100
进行中（未招募）
不适用
A randomized, double-blind study comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs metformin alone in patients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statin - fenofibrate and metformin fixed combination vs metformiPatients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statinEUCTR2006-000924-15-HUFOURNIER Laboratories Ireland Ltd480
进行中（未招募）
1 期
Efficacy and safety of trazodone OAD and venlafaxine XR in the treatment of Major Depressive Disorder.Major depressive disorderMedDRA version: 19.0Level: SOCClassification code 10037175Term: Psychiatric disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 19.0Level: HLGTClassification code 10012375Term: Depressed mood disorders and disturbancesSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 19.0Level: HLTClassification code 10012401Term: Depressive disordersSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2011-005878-37-ESAziende Chimiche Riunite Angelini Francesco - ACRAF S.p.A.360